Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $2.07M invested in Can-Fite BioPharma American Depositary Shares in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
119% more capital inflows, than outflows
Capital inflows: $70.1K | Capital outflows: $32K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
0.01% more ownership
Funds ownership: 0.28% → 0.29% (+0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$35K |
| 2 |
Virtu KCG Holdings
New York
|
+$28K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Advisor Group
Phoenix,
Arizona
|
-$10K |
| 2 |
Menta Capital
San Francisco,
California
|
-$7.01K |
| 3 |
Morgan Stanley
New York
|
-$7.01K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$5K |
| 5 |
IFP Advisors
Tampa,
Florida
|
-$3K |
CANF Hedge Fund Activity: Q4 2016 in Review
6 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2016, worth a combined $2.07M — down 8.4% from $2.26M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CANF positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $35K. The largest seller was Advisor Group, exiting entirely with an estimated $10K sold.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2016, up from 5 in Q3 2016.
- Funds reported $2.07M of Can-Fite BioPharma American Depositary Shares stock for Q4 2016, down 8.4% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2016 and 2 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2016 was Citadel Advisors, an estimated $35K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2016 was Advisor Group, an estimated $10K sold.
Based on aggregated 13F filings for Q4 2016.